Janssen STELARA® (ustekinumab) Access Programme

By NZ Gastro Office | Posted: Sunday November 13, 2022

Janssen has asked us to share their decision to open the STELARA Access Programme for adult New Zealand patients with Crohn’s disease or ulcerative colitis, who have been treated previously with either infliximab or adalimumab. This is subject to eligibility criteria and terms and conditions.

As you may already be aware, the recent PHARMAC proposal on the funding of STELARA closed on 26 October 2022. If the proposal is confirmed, funding would commence as of 1 February 2023.

The programme will provide early access to STELARA for New Zealand patients who require immediate initiation on an additional biologic therapeutic option ahead of, what is hoped to be, a funded status for STELARA as of 1 February 2023.

Important information

  1. Patient enrolments must be completed by the treating clinician at www.janssenpro.co.nz
  2. Enrolments are subject to approval and must meet the enclosed criteria which is aligned with the proposed PHARMAC Special Authority criteria
  3. Terms and conditions apply, please see enclosed
  4. Patients are enrolled on the understanding that they will transition from the Access Programme to   the publicly funded schedule (subject to funding being publicly notified and confirmed) as of 1 February 2023.

Please read the attached for further information regarding the STELARA Access Programme